Evidence map›Paper›PMID 34868572›Full record

ArticleAnnals of medicine and surgery (2012)2021

Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report.

Dimitra V Peristeri, Kostas Tepelenis, Anastasia Karampa, Nikolaos Kapodistrias, Anna C Goussia, George Pappas-Gogos, Georgios K Glantzounis

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine and surgery (2012), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dimitra V PeristeriHPB Unit, Department of Surgery, University Hospital of Ioannina and School of Medicine, University of Ioannina, Ioannina, Greece.
Kostas TepelenisHPB Unit, Department of Surgery, University Hospital of Ioannina and School of Medicine, University of Ioannina, Ioannina, Greece.
Anastasia KarampaHPB Unit, Department of Surgery, University Hospital of Ioannina and School of Medicine, University of Ioannina, Ioannina, Greece.
Nikolaos KapodistriasDepartment of Oncology, University Hospital of Patras, Greece.
Anna C GoussiaDepartment of Pathology, University Hospital of Ioannina and School of Medicine, University of Ioannina, Ioannina, Greece.
George Pappas-GogosHPB Unit, Department of Surgery, University Hospital of Ioannina and School of Medicine, University of Ioannina, Ioannina, Greece.
Georgios K GlantzounisHPB Unit, Department of Surgery, University Hospital of Ioannina and School of Medicine, University of Ioannina, Ioannina, Greece.
University of Ioannina · GRGeneral University Hospital of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and importanceMetronomic chemotherapy entails chronic, equally spaced administration of low doses of various chemotherapeutic drugs without extended rest periods. Its use as a second-line treatment in advanced or metastatic hepatocellular cancer remains under investigation. CASE PRESENTATION: We report a case of a 49-year-old Caucasian female patient with an enlarged (∼14 cm) hepatocellular cancer. In July 2016, she underwent right hepatectomy (after preceding TACE). During the follow-up period, she presented early disease recurrence with lung and peritoneal metastasis. Initially, she received an inhibitor of protein kinase (sorafenib) for six months without response. Afterwards, cyclophosphamide administration at low doses as metronomic chemotherapy provided complete regression of the metastatic lesions. The patient remains in good performance status almost 4 years after initial treatment, without signs of recurrence in her recent follow-up. CLINICAL DISCUSSION: Using cyclophosphamide as metronomic chemotherapy in advanced hepatocellular cancer may have a promising antiangiogenic antitumor effect. Future clinical trials need to demonstrate this effect in terms of tumor suppression and increased disease-free survival.

conclusionLarge multi-centered clinical trials have to be planned to investigate the precise role of cyclophosphamide in the therapy of hepatocellular cancer while defining the patients' profile that will benefit most from cyclophosphamide.

Indexed as

Advanced hepatocellular cancerCase reportCyclophosphamideMetronomic chemotherapyRecurrence

Identifiers

PMID34868572
PMCPMC8626568
OpenAlexW3213874455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.